SYRE Spyre Therapeutics Chart, History Price & Graph

Key Takeaways

• SYRE remains in a strong uptrend, with shares up over 112% YTD and 461% over the past year, recently surging on positive clinical data.
• Price action shows a breakout above prior highs, testing resistance near the 52-week high of $75.00.
• Key support levels at $67.65 and $65.00, with nearer resistance at $70.00–$72.38.
• Momentum indicators like RSI around 55 signal neutral conditions amid the rally, while overall technicals lean neutral short-term but buy on weekly/monthly frames.
• Volume spikes accompany the recent advance, indicating strong buying interest.

Trend Analysis

Spyre Therapeutics, Inc. (SYRE) has exhibited a robust bullish trend over the past year, propelled by positive developments in its clinical pipeline. The stock has risen from a 52-week low of $12.28 to near its 52-week high of $75.00, reflecting sustained upward momentum. In the last 30 days, SYRE experienced a sharp breakout, gapping higher by over 25% following favorable ulcerative colitis trial data. This move has positioned the stock in a potential continuation pattern, with higher highs and higher lows intact on the daily chart. Longer-term weekly and monthly timeframes show buy signals, underscoring the prevailing uptrend despite short-term consolidation risks.

Support and Resistance Levels

Traders are closely monitoring key price zones around the current level near $69.70. Immediate resistance clusters at $70.00—a psychological barrier—followed by $71.07–$72.38 based on Fibonacci extensions from recent swings. A sustained break above $75.00, the 52-week high, could signal further upside. On the downside, support emerges at $67.65 (Fibonacci S1), $66.85 (S2), and the critical $65.00 zone where prior buying interest has materialized. Deeper support lies around $60.00, aligning with recent consolidation lows. These levels define the current trading range amid heightened volatility.

Momentum Indicators

Momentum has cooled slightly after the explosive rally, with the Relative Strength Index (RSI) hovering around 55 on the daily chart, indicating neutral conditions neither overbought nor oversold. This follows periods where RSI approached higher levels during the surge. MACD shows a minor negative value around -0.26, suggesting short-term bearish divergence, though the histogram remains constructive in the broader uptrend. Stochastic and other oscillators contribute to a neutral summary on intraday and daily frames, advising caution for new entries until confirmation.

Volume and Market Activity

Trading volume has spiked notably during the recent advance, with over 2 million shares exchanged on key days, well above average. This unusual activity underscores institutional buying on the breakout, providing confirmation of the move's strength. Elevated volume near resistance levels will be pivotal in determining whether SYRE can sustain the uptrend or face profit-taking.

Tickeron’s AI Daily Buy/Sell Signals

Tickeron’s AI Daily Buy/Sell Signals leverage artificial intelligence to scrutinize vast datasets, including technical indicators, price patterns, and historical trends, generating actionable buy or sell signals for stocks like SYRE. These signals draw from trend recognition, momentum shifts, and pattern matching to highlight potential entry and exit points, trend confirmations, and decision-support cues. Traders rely on them to navigate volatile biotech names, filtering noise and aligning with probabilistic edges. Explore the AI Daily Buy/Sell Signals for SYRE to enhance your technical toolkit.

Technical Outlook and Key Levels to Watch

Looking ahead, traders will watch for a decisive move above $70.00–$75.00 to confirm trend continuation, potentially targeting higher Fibonacci extensions. A pullback testing $65.00–$67.65 support could offer buying opportunities if volume holds firm. Monitor RSI for overbought signals above 70 and MACD crossovers for momentum shifts. Breakouts from the current range or volume confirmation will dictate near-term direction in this volatile biotech stock.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.